文献速递肿瘤 PET/CT核素与放射性配体治疗

89Zr标记的PSMA配体用于PSMA-617与PSMA-I&T的药代动力学PET显像和剂量学:临床前评价与首次人体研究

89Zr-labeled PSMA ligands for pharmacokinetic PET imaging and dosimetry of PSMA-617 and PSMA-I&T: a preclinical evaluation and first in man.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2021-12-21

研究建立了用长半衰期正电子发射体89Zr标记PSMA-617和PSMA-I&T的两步标记法,在PSMA+荷瘤小鼠中比较其与相应177Lu标记配体的生物分布,并进行剂量学估算;首次人体89Zr-PSMA-617 PET在注射后48小时内显示PSMA表达组织高对比度。

要点

  • PSMA-617与PSMA-I&T均成功用89Zr标记,PSMA+荷瘤小鼠中摄取高,注射后168小时仍可行PET显像。
  • 89Zr-PSMA-617和89Zr-PSMA-I&T的离体生物分布分别与177Lu-PSMA-617和177Lu-PSMA-I&T相似。
  • 用177Lu剂量估算模型时,177Lu-PSMA与89Zr-PSMA示踪剂在骨和肾脏的吸收辐射剂量存在差异。

核心结论

  • PSMA-617和PSMA-I&T均成功用89Zr标记,在PSMA+荷瘤小鼠中显示高摄取,注射后168小时仍可行PET显像。
  • 89Zr-PSMA-I&T和89Zr-PSMA-617的生物分布分别与177Lu-PSMA-I&T和177Lu-PSMA-617相似。
  • 首例患者89Zr-PSMA-617 PET图像质量高,值得进一步临床研究。

研究设计与样本

  • 临床前评价与首次人体研究:用两步标记法以50-55 MBq [89Zr]ZrCl4标记PSMA配体。
  • 荷瘤BALB/c裸鼠经静脉注射0.6 µg(0.6-1 MBq)的89Zr-PSMA-617、89Zr-PSMA-I&T、177Lu-PSMA-617或177Lu-PSMA-I&T,行离体生物分布与PET/SPECT显像至注射后168小时,并基于生物分布数据行剂量学估算。
  • 一例患者接受90.5 MBq 89Zr-PSMA-617后行PET/CT显像。

主要发现

  • 89Zr标记的PSMA配体离体生物分布与相应177Lu标记物相当,PSMA+荷瘤小鼠中肿瘤摄取高。
  • 采用177Lu剂量估算模型时,177Lu-PSMA与89Zr-PSMA示踪剂在骨和肾脏的吸收辐射剂量存在差异。
  • 首例患者89Zr-PSMA-617 PET在注射后48小时内显示PSMA表达组织高对比度。

临床怎么用

  • 原文结论指出首例患者89Zr-PSMA-617 PET图像质量高,值得进一步临床研究。

局限性

  • 原文结论指出首例患者89Zr-PSMA-617 PET图像质量高,值得进一步临床研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE: Prolonged in vivo evaluation of PSMA tracers could improve tumor imaging and patient selection for 177Lu-PSMA-617 and 177Lu-PSMA-I&T. In this study, we present the radiolabeling method of PSMA-617 and PSMA-I&T with the long-lived positron emitter 89Zr to enable PET imaging up to 7 days post-injection. We compared the biodistribution of 89Zr-PSMA-617 and 89Zr-PSMA-I&T to those of 177Lu-PSMA-617 and 177Lu-PSMA-I&T, respectively, in a PSMA+ xenograft model. Moreover, we provide the first human 89Zr-PSMA-617 images. MATERIALS AND METHODS: PSMA ligands were labeled with 50-55 MBq [89Zr]ZrCl4 using a two-step labeling protocol. For biodistribution, BALB/c nude mice bearing PSMA+ and PSMA- xenografts received 0.6 µg (0.6-1 MBq) of 89Zr-PSMA-617, 89Zr-PSMA-I&T, 177Lu-PSMA-617, or 177Lu-PSMA-I&T intravenously. Ex vivo biodistribution and PET/SPECT imaging were performed up to 168 h post-injection. Dosimetry was performed from the biodistribution data. The patient received 90.5 MBq 89Zr-PSMA-617 followed by PET/CT imaging. RESULTS: 89Zr-labeled PSMA ligands showed a comparable ex vivo biodistribution to its respective 177Lu-labeled counterparts with high tumor accumulation in the PSMA+ xenografts. However, using a dose estimation model for 177Lu, absorbed radiation dose in bone and kidneys differed among the 177Lu-PSMA and 89Zr-PSMA tracers. 89Zr-PSMA-617 PET in the first human patient showed high contrast of PSMA expressing tissues up to 48 h post-injection. CONCLUSION: PSMA-617 and PSMA-I&T were successfully labeled with 89Zr and demonstrated high uptake in PSMA+ xenografts, which enabled PET up to 168 h post-injection. The biodistribution of 89Zr-PSMA-I&T and 89Zr-PSMA-617 resembled that of 177Lu-PSMA-I&T and 177Lu-PSMA-617, respectively. The first patient 89Zr-PSMA-617 PET images were of high quality warranting further clinical investigation.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Privé BM, Derks YHW, Rosar F, et al. 89Zr-labeled PSMA ligands for pharmacokinetic PET imaging and dosimetry of PSMA-617 and PSMA-I&T: a preclinical evaluation and first in man. Eur J Nucl Med Mol Imaging. 2021. PMID: 34932154. doi:10.1007/s00259-021-05661-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。